Avricore Health Recognized in Deloitte’s 2024 Technology Fast 50™ Companies to Watch
06 nov. 2024 15h14 HE
|
Avricore Health Inc.
Avricore earned 8th spot in Deloitte Canada’s 2024 Technology Fast 50™ Companies-to-Watch list, reflecting its significant growth.
Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer
18 déc. 2023 07h30 HE
|
POINT Biopharma
BEDFORD, Mass. and INDIANAPOLIS, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus) (NASDAQ: LNTH) and POINT Biopharma Global Inc. (POINT) (NASDAQ: PNT) today announced...
Avricore Health Corporate Update – Company Demonstrates Strong Growth
30 nov. 2023 12h58 HE
|
Avricore Health Inc.
Avricore Health provides a corporate update and results for the first 9 months of 2023.
HealthTab™ Signs Reseller Agreement With Abbott to Support UK Expansion
08 août 2023 11h54 HE
|
Avricore Health Inc.
VANCOUVER, British Columbia, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) (“Avricore Health” or the “Company”) is pleased to announce the signing of a reseller...
POINT Biopharma and AdvanCell to Collaborate in the Development of Lead-212-Labeled Radioligands
26 juin 2023 07h45 HE
|
POINT Biopharma
INDIANAPOLIS and SYDNEY, Australia, June 26, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and...
Avricore Health Hosts 2023 Annual General Meeting and Welcomes New Board Members
21 juin 2023 18h38 HE
|
Avricore Health Inc.
VANCOUVER, British Columbia, June 21, 2023 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “AVCR”) held its annual general meeting to elect directors, appoint its auditor and...
POINT Biopharma Announces FRONTIER Trial-in-Progress Poster Presentation at ASCO
25 mai 2023 08h30 HE
|
POINT Biopharma
PNT2004 program’s phase 1 FRONTIER trial design to be presented Abstract to be released today at 5:00 PM ET, May 25th Poster to be available starting at 9:00 AM ET, June 3rd INDIANAPOLIS, May 25,...
POINT Biopharma Makes Strategic Investment in Commercial-Scale Alpha-Emitting Isotope Manufacturer
15 mai 2023 07h35 HE
|
POINT Biopharma
INDIANAPOLIS and LANSING, Mich., May 15, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global...
Avricore Health Corporate Updates on Audited Results for 2022
02 mai 2023 07h30 HE
|
Avricore Health Inc.
VANCOUVER, British Columbia, May 02, 2023 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “AVCR”) today is pleased to announce its audited final results for 2022. ...
POINT Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Highlights
27 mars 2023 08h00 HE
|
POINT Biopharma
Signed Strategic Collaboration Agreement with Lantheus Holdings Inc. for POINT's PNT2002 and PNT2003 product candidates Completed enrollment for randomization phase of PNT2002's phase 3 SPLASH...